Letrozole for Brain Tumor

This trial tests letrozole, a drug typically used for breast cancer, to determine if it can penetrate and remain in brain tumors called gliomas. The study consists of different parts: one examines letrozole alone, while another combines it with temozolomide to assess their combined effectiveness. It targets individuals diagnosed with a recurrent high-grade glioma who are planning surgery or a biopsy. Participants should not have severe heart issues or infections and must be free from other experimental treatments. As an Early Phase 1 trial, this research aims to understand how letrozole functions in people with gliomas, offering participants a chance to contribute to groundbreaking cancer research.

The trial information does not specify if you need to stop taking your current medications. However, you cannot be on any other investigational drugs while participating.

Research has shown that letrozole is usually well-tolerated. Earlier studies found that taking up to 10 mg of letrozole daily and a single dose of 30 mg were safe. For this trial, doses up to 20 mg are expected to be safe based on previous research.

When combined with temozolomide, past studies have also shown letrozole to be safe. A daily dose of 15 mg of letrozole has been identified as safe for future studies. Temozolomide, a chemotherapy drug used to treat brain tumors, can have side effects. More serious side effects include low blood cell counts and tiredness, known risks of using temozolomide.

Researchers are excited about letrozole for brain tumors because it offers a novel approach compared to standard treatments like surgery, radiation, and chemotherapy. Unlike other treatments for high-grade gliomas that primarily focus on killing cancer cells directly, letrozole works differently by targeting the production of estrogen, which can fuel the growth of certain tumors. Additionally, when combined with temozolomide, a chemotherapy drug, letrozole might enhance the effectiveness of the treatment by potentially disrupting tumor growth more effectively. This innovative combination could provide a new hope for patients with aggressive brain tumors, offering a potentially safer and more effective treatment option.

Research has shown that letrozole may help treat brain tumors like gliomas. Early tests found that letrozole can shrink tumors by more than 75% in just 8 days. It works by reducing the activity of aromatase, an enzyme that can help tumors grow. In this trial, one group of participants will receive letrozole alone, while another group will receive letrozole combined with temozolomide, another cancer drug. When used with temozolomide, letrozole has been shown to enhance treatment effectiveness by causing more damage to the cancer cells' DNA and improving outcomes. These findings suggest letrozole could be a strong option in fighting aggressive brain cancers.²³⁵⁶⁷